← Back to Search

CAR T-cell Therapy

agenT-797 for Solid Tumors

Phase 1

Recruiting

Research Sponsored by MiNK Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 months

Awards & highlights

Study Summary

This trial is testing a new cancer therapy, agenT-797, to see if it is safe and effective. The trial will also test agenT-797 in combination with other approved cancer therapies, pembrolizumab and nivolumab, to see if it is safe and effective.

Eligible Conditions

Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cell Therapy

Number Of Dose-limiting Toxicities

Number Of Participants With Treatment-emergent Adverse Events (TEAEs)

+2 more

Secondary outcome measures

Duration Of Response (DOR)

Incidence Of Donor-specific Antibody

Incidence Of Panel-reactive Antibody

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Part 2: agenT-797 in Combination with approved ICIsExperimental Treatment2 Interventions

Single prespecified dose of agenT-797 administered by IV infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care

Group II: Part 1: Monotherapy with agenT-797Experimental Treatment1 Intervention

3+3 Dose escalation of agenT-797 will be administered as a single intravenous (IV) infusion.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

agenT-797

2021

Completed Phase 2

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

MiNK TherapeuticsLead Sponsor

2 Previous Clinical Trials

33 Total Patients Enrolled

Medical DirectorStudy DirectorMiNK Therapeutics

2,777 Previous Clinical Trials

8,063,450 Total Patients Enrolled

Media Library

agenT-797 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05108623 — Phase 1

Solid Tumors Research Study Groups: Part 1: Monotherapy with agenT-797, Part 2: agenT-797 in Combination with approved ICIs

Solid Tumors Clinical Trial 2023: agenT-797 Highlights & Side Effects. Trial Name: NCT05108623 — Phase 1

agenT-797 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05108623 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings for participants in this exploration?

"Indeed, the clinicaltrials.gov database reveals that enrollment for this study is ongoing. This trial was first publicized on January 28th 2022 and most recently updated on October 21st 2022; a total of 30 participants must be accepted from 10 different sites."

Answered by AI

To what extent does agenT-797 pose a risk for patients?

"Data on agenT-797's safety and efficacy is restricted, so our team at Power gave it a score of 1."

Answered by AI

Are there any Canadian research centers actively conducting this experiment?

"The medical trial is being hosted in 10 distinct sites, encompassing Norton Cancer Health in Louisville, Weill Cornell Medicine of New york City and University of Southern California at Los Angeles. There are several other locations involved too."

Answered by AI

To what extent is enrollment progressing for this research project?

"The clinical trial requires 30 volunteers meeting the specified eligibility criteria. Potential participants can join from Norton Cancer Health in Louisville, Kentucky and Weill Cornell Medicine in New york, New York among many other locations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

2022. "A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05108623.